Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

MLA

Gustavo Alva, et al. “Skin Reactions at the Application Site of Rivastigmine Patch (4.6 Mg/24 h, 9.5 Mg/24 h or 13.3 Mg/24 h): A Qualitative Analysis of Clinical Studies in Patients with Alzheimer’s Disease.” International Journal of Clinical Practice, vol. 69, Feb. 2015, pp. 518–30. EBSCOhost, https://doi.org/10.1111/ijcp.12621.

APA

Gustavo Alva, Xiangyi Meng, Drew M. Velting, James E. Galvin, & Jeffrey L. Cummings. (2015). Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer’s disease. International Journal of Clinical Practice, 69, 518–530. https://doi.org/10.1111/ijcp.12621

Chicago

Gustavo Alva, Xiangyi Meng, Drew M. Velting, James E. Galvin, and Jeffrey L. Cummings. 2015. “Skin Reactions at the Application Site of Rivastigmine Patch (4.6 Mg/24 h, 9.5 Mg/24 h or 13.3 Mg/24 h): A Qualitative Analysis of Clinical Studies in Patients with Alzheimer’s Disease.” International Journal of Clinical Practice 69 (February): 518–30. doi:10.1111/ijcp.12621.